Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

Vaccine

Volumn 14, Issue 15, 1996, Pages 1451-1458

  Wyatt, Linda S ^a   Shors, Scott T ^a   Murphy, Brian R ^a   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

MVA strain; Parainfluenza virus; Vaccinia virus

Indexed keywords

RECOMBINANT VACCINE; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RAT; VACCINATION; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; HELA CELLS; HUMANS; PARAINFLUENZA VIRUS 3, HUMAN; RESPIROVIRUS INFECTIONS; SIGMODONTINAE; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0030446387     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00072-2     Document Type: Article

References (33)

1. 1 Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 1969, 89, 449-463
2. 2 Murphy, B.R., Hall, S.L., Kulkarni, A.B. et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 1994, 32, 13-36
3. 3 Spriggs, M.K., Murphy, B.R., Prince, G.A., Olmsted, R.A. and Collins, P.L. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J. Virol. 1987, 61, 3416-3423
4. 4 Spriggs, M.K., Collins, P.L., Tierney, E., London, W.T. and Murphy, B.R. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection. J. Virol. 1988, 62, 1293-1296
5. 5 Fenner, F., Henderson, D.A., Arita, I., Jezek, Z. and Ladnyi, I.D. Smallpox and its Eradication. World Health Organization, Geneva, 1988, pp. 1-1460
6. 6 Mayr, A., Hochstein-Mintzel, V. and Stickl, H. Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes MVA. Infection 1975, 3, 6-14
7. 7 Meyer, H., Sutter, G. and Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72, 1031-1038
8. 8 Mayr, A., Stickl, H., Müller, H.K., Danner, K. and Singer, H. Der pockenimpfstamm MVA: Marker, genetische struktur, erfahrungen mit der parenteralen schutzimpfung und verhalten im abwehrgeschwächten organismus. Zbl. Bakt. Hyg. 1978, 1671. Abt. Orig. B, 375-390
9. 9 Sutter, G. and Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. natn. Acad. Sci. U.S.A. 1992, 89, 10847-10851
10. 10 Sutter, G., Wyatt, L.S., Foley, P.L., Bennink, J.R. and Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12, 1032-1040
11. 11 Earl, P.L. and Moss, B. Generation of recombinant vaccinia viruses. In: Current Protocols in Molecular Biology (Eds Ausubel F.M., et al.). Greene Publishing Associates/Wiley Interscience, New York, 1991, pp. 16.17.1-16.17.16
12. 12 Coelingh, K.V.W., Winter, C.C., Murphy, B.R. et al. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J. Virol. 1986, 60, 90-96
13. 13 Prince, G.A., Jenson, A.B., Hemming, V.G. et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 1986, 57, 721-728
14. 14 Rosel, J.L., Earl, P.L., Weir, J.P. and Moss, B. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the Hindlll H genome fragment. J. Virol. 1986, 60, 436-439
15. 15 Taylor, J., Weinberg, R., Kawaoka, Y., Webster, R.G. and Paoletti, E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine 1988, 6, 504-508
16. 16 Guo, P., Goebel, S., Davis, S. et al. Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals. J. Virol. 1989, 63, 4189-4198
17. 17 Perkus, M.E., Limbach, K. and Paoletti, E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J. Virol. 1989, 63, 3829-3836
18. 18 Davison, A.J. and Moss, B. The structure of vaccinia virus late promoters. J. molec. Biol. 1989, 210, 771-784
19. 19 Ebata, S.N., Cote, M.-J., Kang, C.Y. and Dimock, K. The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion. Virology 1991, 183, 437-441
20. 20 Moscona, A. and Peluso, R.W. Fusion properties of cells persistently infected with human parainfluenza virus type 3: participation of hemagglutinin-neuraminidase in membrane fusion. J. Virol. 1991, 65, 2773-2777
21. 21 Hu, X., Ray, R. and Compans, R.W. Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses. J. Virol. 1992, 66, 1528-1534
22. 22 Redfield, R.R., Wright, D.C., James, W.D., Jones, T.S., Brown, C. and Burke, D.S. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 1987, 316, 673-676
23. 23 Buller, R.M.L., Smith, G.L., Cremer, K., Notkins, A.L. and Moss, B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985, 317, 813-815
24. 24 Buller, R.M., Chakrabarti, S., Cooper, J.A., Twardzik, D.R. and Moss, B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J. Virol. 1988, 62, 866-877
25. 25 Tartaglia, J., Perkus, M.E., Taylor, J. et al. NYVAC - a highly attenuated strain of vaccinia virus. Virology 1992, 188, 217-232
26. 26 Taylor, J., Weinberg, R., Tartaglia, J. et al. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1987, 187, 321-328
27. 27 Stickl, H., Hochstein-Mintzel, V., Mayr, A., Huber, H.C., Schäfer, H. and Holzner, A. MVA-stufenimpfung gegen pocken. Kleinische erprobung des attenuierten pocken-lebendimpfstoffes, stamm MVA. Dtsch. Med. Wschr. 1974, 99, 2386-2392
28. 28 Coupar, B.E.H., Andrew, M.E., Both, G.W. and Boyle, D.B. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur. J. Immun. 1986, 16, 1479-1487
29. 29 Townsend, A., Bastin, J., Gould, K. et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. exp. Med. 1988, 168, 1211-1224
30. 30 Small, P.A., Smith, G.L. and Moss, B. Intranasal vaccination with a recombinant vaccinia virus containing influenza hemagglutinin prevents both influenza virus pneumonia and nasal infection: intradermal vaccination prevents only viral pneumonia. In: Vaccines 85 (Eds Lerner, R.A., Chanock, R.M. and Brown, F.). Cold Spring Harbor Laboratory, Cold Spring Harbor, 1985, pp. 175-176
31. 31 Kanesaki, T., Murphy, B.R., Collins, P.L. and Ogra, P.L. Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus. J. Virol. 1991, 65, 657-663
32. 32 Nussbaum, O., Broder, C.C. and Berger, E.A. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J. Virol. 1994, 68, 5411-5422
33. 33 Chakrabarti, S., Brechling, K. and Moss, B. Vaccinia virus expression vector: coexpression of B-galactosidase provides visual screening of recombinant virus plaques. Molec. Cell. Biol. 1985, 5, 3403-3409